MedPath

Phantom Neuro's Neural Interface Platform Receives Dual FDA Fast-Track Designations for Prosthetic Control

• Phantom Neuro's minimally invasive Phantom X platform has secured both FDA Breakthrough Device and TAP Designations, accelerating its path to market for advanced prosthetic control technology.

• The neural interface system demonstrated 94% accuracy in decoding 11 essential hand and wrist movements in the recent ASCENT study, showing promise for intuitive prosthetic control.

• The platform's outpatient procedure design makes it accessible to over 70,000 qualified surgeons nationwide, potentially transforming care for amputees and those with mobility challenges.

Phantom Neuro has achieved a significant regulatory milestone as its innovative neural interface platform, Phantom X, receives dual recognition from the FDA through both Breakthrough Device and Targeted Acceleration Pathway (TAP) Designations. These prestigious designations position the Austin-based neurotechnology company to accelerate the development of its minimally invasive solution for advanced prosthetic control.
The Phantom X platform represents a breakthrough in human-machine interface technology, designed to enable intuitive control of prosthetic limbs and robotic devices. The system's distinguishing feature lies in its minimally invasive approach, requiring only a simple outpatient procedure for implantation just beneath the skin.

Clinical Performance and Technological Innovation

Recent data from the company's ASCENT study has demonstrated the platform's remarkable capabilities, achieving 94% accuracy in real-time gesture decoding across 11 essential hand and wrist movements. This level of precision suggests a significant advancement in prosthetic control technology, potentially offering users more natural and intuitive movement capabilities.
"Receiving both of these certified designations from the FDA is a tremendous validation of our work," said Dr. Connor Glass, Founder and CEO of Phantom Neuro. "These recognitions validate our technology and reflect our commitment to creating scalable, real-world solutions that restore functionality and independence to amputees and those with functional disabilities."

Regulatory Significance and Market Access

The FDA's dual designation carries substantial implications for Phantom Neuro's development timeline. The Breakthrough Device Designation acknowledges the platform's potential advantages over existing solutions, while the more selective TAP Designation enables strategic communication with the FDA, potentially streamlining the regulatory review process.

Accessibility and Implementation

A key advantage of the Phantom X platform is its broad accessibility. The minimally invasive nature of the implantation procedure makes it feasible for over 70,000 qualified surgeons across the United States to perform the installation, potentially democratizing access to advanced prosthetic control technology.

Future Development

Building on its current momentum, Phantom Neuro plans to advance its clinical development program with additional trials scheduled for 2025. The company's technology pipeline aims to expand the possibilities for individuals with limb loss and severe mobility impairments, focusing on enhancing independence and quality of life through improved prosthetic control.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

OrthoPreserve's Meniscus Implant, Defender, Receives FDA Breakthrough Device Designation and TAP Enrollment

OrthoPreserve's Defender implant received FDA Breakthrough Device Designation and TAP enrollment for treating post-meniscectomy knee pain and impairment.
The implant addresses a significant treatment gap for patients who experience poor outcomes after standard meniscus surgeries, potentially delaying or preventing knee replacements.

FDA Grants Breakthrough Device Designations for Novel Neuromodulation Therapies Targeting PTSD and MDD

Wave Neuroscience's MeRT system received FDA Breakthrough Device Designation for adjunctive treatment of PTSD, addressing the critical need for effective, non-pharmacologic options.
Pulvinar Neuro, a subsidiary of EPI, obtained FDA Breakthrough Device Designation for its Closed-Loop tACS device, aiming to provide rapid relief from Major Depressive Disorder (MDD) symptoms.

UNEEG Medical's Subcutaneous EEG Implant System Receives FDA Breakthrough Device Designation for Epilepsy Monitoring

UNEEG Medical's Subcutaneous EEG Implant System has received FDA Breakthrough Device Designation, expediting its review for treating severe epilepsy.
The system offers continuous 24/7 EEG recording via a small subcutaneous device, providing long-term brain activity data for physicians.

QuantalX's Delphi Stimulator Receives FDA Clearance for Advancing Brain Health Diagnosis

QuantalX has received FDA clearance for its Delphi stimulator, a novel device designed for direct brain health diagnosis at the point of care.
The Delphi-MD platform enables early detection of brain abnormalities across conditions like stroke, dementia, Parkinson's Disease, and traumatic brain injury.

Momentis Surgical Receives FDA Clearance for Second-Generation Anovo Robotic Surgery Platform

Momentis Surgical secured FDA 510(k) clearance for its second-generation Anovo robotic surgery platform, enhancing surgical capabilities through a single incision.
The upgraded Anovo system offers improved ergonomics, sensory feedback, and a video annotation layer to boost surgical team communication and learning.

NeurAxis Receives Expanded FDA Clearance for IB-Stim in Abdominal Pain Relief

NeurAxis has secured an expanded FDA 510(k) clearance for its IB-Stim device, a non-implanted nerve stimulator, to broaden its application in functional abdominal pain relief.
The expanded clearance increases the addressable market for IB-Stim by approximately 75% and allows for the use of up to four devices per patient, according to NeurAxis.

Sanbexin Sublingual Tablets Granted FDA Breakthrough Therapy Designation for Ischemic Stroke

Simcere Pharmaceuticals' Sanbexin sublingual tablets receive Breakthrough Therapy designation from the FDA for ischemic stroke treatment.
The designation aims to expedite the development and regulatory review of Sanbexin, addressing a critical unmet need in stroke therapy.

Neuraptive's NTX-001 Receives FDA Breakthrough Therapy Designation for Peripheral Nerve Injury

NTX-001, a drug-device combination by Neuraptive Therapeutics, has received Breakthrough Therapy Designation from the FDA for treating peripheral nerve injuries requiring repair.
The designation was granted based on promising Phase 2 NEUROFUSE study results, potentially accelerating NTX-001's development and review process.

FDA Clears AI-Powered Brain Mapping Tool for Personalized Neuromodulation Therapies

Turing Medical's Bullsai Identify, an AI-driven platform, has received FDA clearance for creating personalized brain maps used in neuromodulation therapies.
The platform analyzes advanced MRI data to map individual brain structures, aiming to improve the precision and efficacy of treatments like deep brain stimulation (DBS).

CereVasc's eShunt System Receives FDA Breakthrough Device Designation for Normal Pressure Hydrocephalus

CereVasc's eShunt System has been granted Breakthrough Device Designation by the FDA for treating Normal Pressure Hydrocephalus (NPH).
The designation facilitates priority review and enhanced communication with the FDA during clinical trials and premarket assessment.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy